BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $80.96
  • 50 Day Moving Average: $92.36
  • 200 Day Moving Average: $89.60
  • 52-Week Range: $62.12 - $118.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -77.12
  • P/E Growth: -0.82
  • Market Cap: $13.34B
  • Outstanding Shares: 163,465,000
  • Beta: 1.34
  • Net Margins: -54.53%
  • Return on Equity: -11.99%
  • Return on Assets: -7.57%
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 3.03%
  • Quick Ratio: 2.14%
Additional Links:
Companies Related to BioMarin Pharmaceutical:

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 3 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.81)
Consensus Price Target: $119.50 (46.18% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateFirmActionRatingPrice TargetDetails
10/15/2016Robert W. BairdSet Price TargetBuy$115.00View Rating Details
10/13/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details
10/7/2016Goldman Sachs Group Inc.UpgradeNeutralView Rating Details
9/8/2016Cowen and CompanySet Price TargetBuy$150.00View Rating Details
9/7/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
9/6/2016WedbushReiterated RatingNeutral$108.00 -> $104.00View Rating Details
8/19/2016Piper Jaffray Cos.Reiterated RatingOverweightView Rating Details
8/17/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/8/2016Credit Suisse Group AGSet Price TargetBuy$111.00View Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00View Rating Details
8/5/2016Barclays PLCBoost Price TargetOverweight$105.00 -> $125.00View Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00View Rating Details
6/20/2016Oppenheimer Holdings Inc.Reiterated RatingMarket Perform$99.00View Rating Details
5/31/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details
1/15/2016Bank of America Corp.Reiterated RatingBuy$165.00 -> $135.00View Rating Details
10/13/2015Raymond James Financial Inc.Reiterated RatingOutperform$157.00View Rating Details
8/6/2015Deutsche Bank AGReiterated RatingBuy$160.00View Rating Details
8/4/2015NomuraReiterated RatingBuy$163.00 -> $173.00View Rating Details
8/4/2015SunTrust Banks Inc.Reiterated RatingBuyView Rating Details
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details
1/29/2015Evercore ISIInitiated CoverageBuyView Rating Details
11/3/2014Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
(Data available from 10/26/2014 forward)


Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316($0.38)$289.70 millionN/AView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
Current Year EPS Consensus Estimate: $-3.95 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.41)
Q4 20165($0.67)($0.26)($0.50)
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 93.17%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateHeadline logo10 Most Successful Innovative Companies in The World in 2016 (NASDAQ:BMRN) - October 26 at 3:55 PM
News Icon2 Biotech Stocks News And Price Trends: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Omeros Corporation ... - The Voice Registrar (NASDAQ:BMRN) - October 26 at 12:51 PM
News IconTop Gainers of the Day: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology (NASDAQ:BMRN) - October 25 at 9:09 PM
News IconNewsmaking Penny Stock: Investors Checking Out BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Duncan Research (NASDAQ:BMRN) - October 25 at 3:54 PM logoMerck (MRK) Beats on Q3 Earnings & Revenues, Lifts View (NASDAQ:BMRN) - October 25 at 3:54 PM
News Icon13F Activity: Biomarin Pharmaceutical INC (BMRN) Shares Declined ... - Chester News (NASDAQ:BMRN) - October 25 at 8:45 AM
News IconWhat is the Sell-side Saying About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)? - CSZ News (NASDAQ:BMRN) - October 24 at 3:51 PM
News IconAnalysts Valuations For Two Stocks: Boston Scientific Corporation (NYSE:BSX), BioMarin Pharmaceutical Inc ... - The Voice Registrar (NASDAQ:BMRN) - October 24 at 8:50 AM
News IconIs BioMarin Pharmaceutical Inc.(NASDAQ: BMRN), a large market cap stock a smart buy? - The Daily Leicester (NASDAQ:BMRN) - October 24 at 8:50 AM
News IconBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) – Is this large market cap stock undervalued? - The Daily Leicester (NASDAQ:BMRN) - October 22 at 8:10 AM logoCommit To Buy BioMarin Pharmaceutical At $65, Earn 8.6% Using Options (NASDAQ:BMRN) - October 21 at 3:53 PM logoWhat's in Store for BioMarin (BMRN) This Earnings Season? (NASDAQ:BMRN) - October 21 at 3:53 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology – Todays Top Gains (NASDAQ:BMRN) - October 21 at 3:53 PM logoAlkermes Depression Candidate Positive in Phase III Study (NASDAQ:BMRN) - October 21 at 12:10 PM logoBiomarin Comes Up Short With Vosoritide - Seeking Alpha (NASDAQ:BMRN) - October 20 at 8:47 PM logoBioMarin Could Reap $1.1 Billion In 2025 On 'Dwarfism' Drug: Analyst (NASDAQ:BMRN) - October 20 at 3:24 PM
News IconA Look At The Science Behind BioMarin Pharmaceutical Inc. (BMRN)’s Next Pivotal Candidate (NASDAQ:BMRN) - October 20 at 11:59 AM
News IconStocks with Active Concerns- Freeport-McMoRan (NYSE:FCX), BioMarin Pharmaceutical (NASDAQ:BMRN), Fluor ... - Seneca Globe (NASDAQ:BMRN) - October 20 at 9:46 AM logoBioMarin Pharma (BMRN) Presents Updated Vosoritide Phase 2 Data in Achondroplasia; Mean Annualized Growth ... - (NASDAQ:BMRN) - October 20 at 9:46 AM logo3 Top Stocks for Your Roth IRA (NASDAQ:BMRN) - October 19 at 8:47 AM
News IconUpdate on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for the day (NASDAQ:BMRN) - October 18 at 3:51 PM logoBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $5.6 million of Shares (NASDAQ:BMRN) - October 18 at 8:44 AM
News IconShare Value Diminishing Over Past Month: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - CSZ News (NASDAQ:BMRN) - October 16 at 8:38 AM
News IconBioMarin Pharmaceutical Inc.'s (BMRN) — Investors Focused Stock (NASDAQ:BMRN) - October 15 at 8:44 AM logoBioMarin Pharmaceutical : UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A (NASDAQ:BMRN) - October 14 at 3:48 PM
News IconHigh Market Cap Stock of the Day – BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (NASDAQ:BMRN) - October 14 at 3:48 PM logoBioMarin Pharmaceutical Enters Oversold Territory (BMRN) (NASDAQ:BMRN) - October 14 at 2:52 PM
News IconTwo Biotech Stocks Are Just So Hot Right Now: BioMarin Pharmaceutical Inc. (BMRN), Cerus Corporation (CERS) - The Independent Republic (NASDAQ:BMRN) - October 14 at 12:21 PM
News IconTrading the Biotech News: BioMarin Pharmaceutical Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:BMRN) - October 14 at 12:21 PM logoBioMarin Pharma (BMRN) Announces MHRA in UK Approves Continued Enrollment in 1/2 Study of BMN 270 in ... - (NASDAQ:BMRN) - October 13 at 9:07 PM logo4:02 pm BioMarin Pharm announces that the Medicines and Healthcare Products Regulatory Agency in the UK approved continued enrollment into the open-label Phase 1/2 study of BMN 270 for severe hemophilia A (NASDAQ:BMRN) - October 13 at 9:07 PM logoUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A (NASDAQ:BMRN) - October 13 at 9:07 PM
News IconTwo Biotechnology Names Are Hot: ACADIA Pharmaceuticals Inc. (ACAD), BioMarin Pharmaceutical Inc. (BMRN) - The Independent Republic (NASDAQ:BMRN) - October 13 at 3:47 PM logoPardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics (NASDAQ:BMRN) - October 13 at 3:47 PM logoSupernus (SUPN) Reports Encouraging Data from ADHD Study (NASDAQ:BMRN) - October 13 at 3:47 PM
News Icon2 Stocks Attracting Analyst Attention: Apache Corporation (NYSE:APA), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - The Voice Registrar (NASDAQ:BMRN) - October 13 at 10:54 AM logoAMAG Issues Encouraging Updates on Makena & Feraheme (NASDAQ:BMRN) - October 13 at 10:54 AM logoBioMarin Pharma (BMRN): Four Domain Field Data Stronger Than Previous Two Domain Data - Leerink (NASDAQ:BMRN) - October 12 at 4:08 PM logo3 biotech breakouts (NASDAQ:BMRN) - October 11 at 3:57 PM logoBioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET (NASDAQ:BMRN) - October 11 at 3:57 PM logoWedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51 - Benzinga (NASDAQ:BMRN) - October 10 at 3:47 PM
News IconBioMarin Pharmaceutical Inc. (BMRN) Stock Up After Upgrade at Goldman Sachs Group Inc. - BNB Daily (blog) (NASDAQ:BMRN) - October 10 at 3:47 PM logoWedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51 (NASDAQ:BMRN) - October 10 at 8:40 AM
News IconIs BioMarin Pharmaceutical Inc.(NASDAQ: BMRN), a large market ... - The Daily Leicester (NASDAQ:BMRN) - October 7 at 3:50 PM
News IconTwo Biotechnology Names Are Hot: BioMarin Pharmaceutical Inc. (BMRN), Progenics Pharmaceuticals, Inc. (PGNX) - The Independent Republic (NASDAQ:BMRN) - October 7 at 8:46 AM
News Icon2 Biotech Stocks News And Price Trends: BioMarin Pharmaceutical ... - The Voice Registrar (NASDAQ:BMRN) - October 6 at 3:49 PM
News IconBiotech news that matter for investors: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sangamo Biosciences Inc ... - The Voice Registrar (NASDAQ:BMRN) - October 6 at 3:49 PM logoWhy Sarepta's Licensing Deal Makes This Drug Maker An "Even More Attractive M&A Candidate" (NASDAQ:BMRN) - October 4 at 3:50 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology – Todays Top Gains - Twin County News (NASDAQ:BMRN) - October 3 at 8:38 AM
News IconTrader's Buzzer: Agenus Inc. (NASDAQ:AGEN), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Newburgh Press (NASDAQ:BMRN) - September 30 at 4:21 PM


BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff